These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38943626)

  • 1. Development of Degraders of Cyclin-Dependent Kinases
    He H; Zhang X; Wang J; Liu Q; Zhang L; Chen L; Yuan Y; Zhao Z; Li H; Chen Z
    J Med Chem; 2024 Jul; 67(13):11354-11364. PubMed ID: 38943626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
    Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
    Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of pteridin-7(8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity.
    Li Q; Chen L; Ma YF; Jian XE; Ji JH; You WW; Zhao PL
    Bioorg Chem; 2021 Nov; 116():105324. PubMed ID: 34509794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
    Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
    Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.
    Jiang B; Wang ES; Donovan KA; Liang Y; Fischer ES; Zhang T; Gray NS
    Angew Chem Int Ed Engl; 2019 May; 58(19):6321-6326. PubMed ID: 30802347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
    Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
    Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
    Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
    Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
    Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Han Y; Xiao W; Wang Z; Shi W; Mao Y; Yu J; Xia G; Liu Y
    Eur J Med Chem; 2019 Sep; 178():352-364. PubMed ID: 31200237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities.
    Liang JW; Li WQ; Nian QY; Xie SH; Yang L; Meng FH
    Bioorg Chem; 2022 Feb; 119():105547. PubMed ID: 34906858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
    Guan H; Du Y; Han W; Shen J; Li Q
    Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6.
    Ji J; Qin J; Wang X; Lv M; Hou X; Jing A; Zhou J; Zuo L; Liu W; Feng J; Qian Q; Liu Y; Wang X; Liu B
    Anticancer Agents Med Chem; 2024; 24(6):400-411. PubMed ID: 38192142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X; Quan Y; Wang Y; Wang Y; Li Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study.
    Susanti NMP; Kurniawan F; Damayanti S; Kartasasmita RE; Tjahjono DH
    Sci Rep; 2024 Oct; 14(1):23505. PubMed ID: 39379427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
    Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
    Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ring-Contracted Artemisinin Derivatives as Novel CDK 4/6 Inhibitors: Synthesis and Anti-Breast Cancer Evaluation.
    Zhu JJ; Ai Y; Wu JH; Zeng CG; Cui Z; Zhang ZP; Zhu JY; Wang CQ; Zhong H
    Chem Biodivers; 2024 Jun; 21(6):e202400086. PubMed ID: 38619074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.